TargetBeta
PARP3
poly(ADP-ribose) polymerase family member 3 · also ADPRT3, IRT1, hPARP-3, pADPRT-3 · Poly(ADP-ribose) polymerases
1 program in company-led studies act on PARP3, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| olaparibrule | AstraZeneca | inhibitor | phase 4 | 7823 running | PARP1, PARP2 | ChEMBL |
Conditions their studies are in
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Neoplasms, 1 program
- Ovarian Neoplasms, 1 program
- Prostatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027olaparib · AstraZeneca · phase 4 · NCT07371104
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.